CJC-1295 Peptide: The Long-Acting GHRH Analog Driving GH Research

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), the 44-amino acid peptide produced by the hypothalamus that stimulates growth hormone (GH) secretion from anterior pituitary somatotroph cells. Specifically, CJC-1295 is a modified version of the first 29 amino acids of GHRH (known as GRF 1-29 or sermorelin) with four amino acid substitutions at positions 2, 8, 15, and 27 that dramatically increase resistance to enzymatic degradation by dipeptidyl peptidase IV (DPP-IV).

The fundamental problem with natural GHRH and its early analog sermorelin is rapid proteolytic degradation. Native GHRH has a plasma half-life of approximately 7 minutes, meaning that within half an hour of secretion, over 90% has been broken down by circulating enzymes. This ultra-short half-life limits the duration and magnitude of GH release. Sermorelin improved upon native GHRH slightly, but its half-life remains under 30 minutes — requiring multiple daily injections to maintain elevated GH output.

CJC-1295 solved this problem through two innovations: (1) the four amino acid substitutions that make the peptide resistant to DPP-IV cleavage, extending the baseline half-life to approximately 30 minutes, and (2) the optional addition of a Drug Affinity Complex (DAC) — a maleimidopropionic acid linker that allows CJC-1295 to covalently bind to serum albumin after injection. The albumin-bound form has a half-life of 6-8 days, producing sustained GH elevation from a single injection. This pharmacokinetic transformation — from a 7-minute natural hormone to a week-long synthetic analog — is what distinguishes CJC-1295 peptide research from earlier GHRH analog work. For foundational context on how growth hormone peptides interact with the endocrine system, see our comprehensive peptide guide.

Understanding the distinction between the two forms of CJC-1295 is critical for interpreting research protocols and outcomes:

CJC-1295 with DAC

The DAC (Drug Affinity Complex) version contains a reactive maleimide group that forms a covalent bond with a lysine residue on serum albumin within minutes of subcutaneous injection. This albumin bioconjugation achieves several effects: (1) it dramatically extends half-life to 6-8 days, (2) it creates a sustained-release reservoir that slowly liberates active peptide, and (3) it protects the peptide from further enzymatic degradation while bound. The result is a continuous, elevated baseline of GH secretion rather than the pulsatile pattern produced by natural GHRH.

A Phase II clinical trial published in the Journal of Clinical Endocrinology and Metabolism (2006) demonstrated that a single 60 μg/kg subcutaneous injection of CJC-1295 DAC increased mean GH levels by 2-10 fold for 6 or more days, with IGF-1 levels elevated by 1.5-3 fold for 9-11 days. Two weekly injections over 4 weeks produced a sustained 46% increase in mean GH secretion and a 45% increase in IGF-1 levels.

CJC-1295 Without DAC (Modified GRF 1-29)

The version without DAC — often marketed as "Mod GRF 1-29" — retains the four DPP-IV-resistant amino acid substitutions but lacks the albumin-binding linker. This gives it a half-life of approximately 30 minutes — far longer than native GHRH but dramatically shorter than the DAC version. Importantly, this shorter half-life preserves the natural pulsatile pattern of GH release rather than producing continuous elevation.

Modified GRF 1-29 is typically administered 2-3 times daily (often at bedtime and upon waking) to amplify the natural GH pulses that occur during sleep and in the early morning. This pulsatile approach more closely mimics physiological GH secretion, which may reduce the risk of GH-related side effects (water retention, insulin resistance) associated with continuous GH elevation.

The choice between DAC and non-DAC versions involves a fundamental tradeoff: convenience and sustained elevation (DAC) versus physiological pulsatility and potentially better tolerance (no DAC). Most contemporary research protocols favor Modified GRF 1-29 (without DAC), often in combination with a growth hormone secretagogue (GHRP) like ipamorelin for synergistic GH release. Explore GH-mediated body composition effects in our peptides for muscle growth guide.

CJC-1295 stimulates GH release through the same receptor pathway as natural GHRH, but with enhanced pharmacokinetics:

GHRH Receptor Activation

CJC-1295 binds to the GHRH receptor (GHRH-R) on anterior pituitary somatotroph cells. This receptor is a G-protein coupled receptor (GPCR) that, upon activation, triggers intracellular cAMP production via adenylyl cyclase. Elevated cAMP activates protein kinase A (PKA), which phosphorylates ion channels and transcription factors that drive GH gene transcription, GH synthesis, and GH vesicle exocytosis. The binding affinity of CJC-1295 for GHRH-R is comparable to native GHRH, meaning the enhanced effects are attributable to prolonged receptor stimulation rather than increased potency per binding event.

GH Pulsatility Amplification

In the case of Modified GRF 1-29 (no DAC), the peptide amplifies existing GH pulses rather than creating new ones. GH secretion is naturally pulsatile, with major bursts during deep sleep (stages 3 and 4) and smaller pulses throughout the day. By providing GHRH receptor stimulation timed to coincide with these natural pulses, Mod GRF 1-29 increases both the amplitude and duration of each GH burst. This pulse-amplification model is significant because it means the peptide works with the body's natural regulatory system rather than overriding it.

Somatostatin Interaction

GH secretion is regulated by the balance between stimulatory (GHRH) and inhibitory (somatostatin) hypothalamic signals. CJC-1295 increases the stimulatory input but does not suppress somatostatin — meaning the body retains its ability to modulate GH output through the inhibitory arm. This preserved negative feedback is a safety feature that distinguishes GHRH analogs from direct GH administration, which bypasses all hypothalamic-pituitary regulation.

IGF-1 Cascade

The downstream effects of CJC-1295-stimulated GH release are mediated primarily through insulin-like growth factor 1 (IGF-1). GH stimulates hepatic IGF-1 production, and IGF-1 mediates many of GH's anabolic effects including muscle protein synthesis, bone mineralization, and cartilage growth. IGF-1 also provides negative feedback to the pituitary, helping to prevent excessive GH elevation — another self-regulatory mechanism preserved by GHRH analog-based GH stimulation. Learn more about how GH-releasing peptides support recovery in our peptide therapy guide.

Published research on CJC-1295 peptide has documented several benefits related to its growth hormone-amplifying effects — all for research purposes only:

Body Composition: The most consistent finding across CJC-1295 research is improved body composition — increased lean mass and decreased fat mass. The Phase II clinical trial (Teichman et al., 2006) demonstrated sustained IGF-1 elevation of 45% over 4 weeks, which in parallel studies correlates with 3-5% increases in lean mass and 5-8% decreases in abdominal fat over similar time frames. These effects are mediated through GH's dual actions: stimulating muscle protein synthesis (anabolic) while activating hormone-sensitive lipase in adipose tissue (lipolytic).

Recovery and Tissue Repair: Elevated GH and IGF-1 levels accelerate recovery from exercise-induced muscle damage, soft tissue injuries, and surgical procedures. GH promotes collagen synthesis in tendons and ligaments, increases satellite cell activation for muscle repair, and enhances protein synthesis rates. Research subjects report improved recovery between training sessions and faster resolution of minor injuries, though controlled human data specific to CJC-1295 (rather than GH in general) is still limited.

Sleep Quality: GH secretion and deep sleep are intimately linked — the largest GH pulse occurs during the first deep sleep cycle, and GH itself promotes deeper, more restorative sleep. CJC-1295, particularly Modified GRF 1-29 dosed before bed, amplifies this nocturnal GH pulse. Research subjects consistently report improved sleep quality, though objective polysomnographic data specific to CJC-1295 is limited. Explore peptide-sleep connections in our sleep peptides guide.

Bone Density: GH and IGF-1 are essential for bone mineralization and remodeling. While long-term bone density data specific to CJC-1295 is lacking, the sustained IGF-1 elevation it produces mimics the GH-IGF-1 axis stimulation that has been shown in GH replacement studies to increase bone mineral density by 3-5% over 12-18 months. This is particularly relevant for aging populations where declining GH contributes to osteoporotic bone loss.

Immune Function: GH receptors are expressed on immune cells including T-cells, B-cells, and natural killer cells. GH stimulation enhances thymic function, T-cell proliferation, and antibody production. Age-related GH decline (somatopause) contributes to immunosenescence — the gradual deterioration of immune function with age. By restoring more youthful GH levels, CJC-1295 may partially counteract age-related immune decline.

Dosing protocols for CJC-1295 differ significantly between the DAC and non-DAC versions, reflecting their vastly different pharmacokinetic profiles:

CJC-1295 DAC Dosing

Clinical trial data used doses of 30-60 μg/kg body weight administered subcutaneously once or twice weekly. For a 75 kg individual, this translates to approximately 2-4.5 mg per injection. The long half-life (6-8 days) means that once-weekly dosing produces sustained GH and IGF-1 elevation without troughs. Research protocols typically run 4-12 weeks with periodic blood work monitoring GH, IGF-1, fasting glucose, and insulin levels.

Modified GRF 1-29 (No DAC) Dosing

The most commonly cited research protocol for Modified GRF 1-29 uses 100-300 μg per injection, administered subcutaneously 2-3 times daily. Standard timing includes injections upon waking (fasted), post-exercise, and at bedtime. The bedtime dose is considered most important because it amplifies the natural nocturnal GH pulse. Each injection should be administered on an empty stomach (or at least 2 hours post-meal), as elevated blood glucose and insulin blunt the GH response to GHRH receptor stimulation.

Combination Protocols: CJC-1295 + Ipamorelin

The most popular research protocol pairs Modified GRF 1-29 with ipamorelin (a selective growth hormone secretagogue receptor agonist) at matching doses of 100-300 μg each, administered simultaneously. This combination produces synergistic GH release because it stimulates GH secretion through two different receptor systems simultaneously: GHRH-R (CJC-1295) and GHS-R/ghrelin receptor (ipamorelin). Published data shows this combination produces GH pulses 3-5 fold greater than either peptide alone.

Regardless of protocol, reconstitution with bacteriostatic water follows standard peptide preparation practices. Use our peptide calculator to determine precise dilution volumes for the desired concentration. For guidance on injection technique, see our peptide injections guide.

CJC-1295's side effect profile is primarily related to the downstream effects of elevated growth hormone rather than the peptide itself:

Water Retention: The most commonly reported side effect, occurring in 20-40% of subjects. GH promotes sodium and water retention through renal mechanisms, producing mild peripheral edema, weight gain (1-3 kg of water), and occasionally carpal tunnel-like symptoms from fluid accumulation around the median nerve. These effects are dose-dependent and typically resolve with dose reduction or discontinuation. The DAC version produces more persistent water retention due to its continuous GH elevation profile.

Fasting Glucose Elevation: GH is a counter-regulatory hormone that opposes insulin's action on glucose uptake. Chronic GH elevation can increase fasting blood glucose by 5-15 mg/dL and reduce insulin sensitivity. In the Phase II clinical trial, CJC-1295 DAC produced a transient increase in fasting glucose that remained within normal ranges for most subjects. However, individuals with pre-existing insulin resistance or pre-diabetes may experience clinically significant glucose elevation. Regular fasting glucose monitoring is recommended during CJC-1295 research protocols.

Injection Site Reactions: Mild redness, itching, and swelling at injection sites are reported in 15-30% of subjects. CJC-1295 DAC may cause slightly more injection site reactions due to the DAC component's tissue irritation. Standard site rotation and proper injection technique minimize these effects.

Headache and Flushing: Transient headache (10-15% incidence) and facial flushing (5-10% incidence) are reported, particularly with initial doses. These effects are attributed to the vasodilatory properties of GH and GHRH and typically diminish with continued use. Adequate hydration reduces headache frequency.

Cortisol and Prolactin: Unlike GHRP-6 and hexarelin (which stimulate cortisol and prolactin alongside GH), CJC-1295 has minimal effect on cortisol and prolactin secretion. This selectivity is a significant advantage — elevated cortisol promotes muscle catabolism and fat storage, while elevated prolactin can cause gynecomastia and sexual dysfunction. The CJC-1295 + ipamorelin combination maintains this selectivity, as ipamorelin is the most GH-selective secretagogue. Explore other selective GH-related peptides in our tesamorelin guide.

Positioning CJC-1295 within the broader landscape of GH-modulating compounds clarifies its unique advantages and limitations:

CJC-1295 vs. Direct GH Administration: Exogenous GH (somatropin) provides the most potent and predictable GH elevation but completely bypasses hypothalamic-pituitary regulation. This eliminates the negative feedback mechanisms that prevent excessive GH levels, increasing the risk of side effects including insulin resistance, joint pain, and potential tumor promotion. CJC-1295, by stimulating the pituitary to release its own GH, preserves somatostatin-mediated negative feedback — meaning the body retains the ability to prevent dangerously high GH levels.

CJC-1295 vs. Sermorelin: Sermorelin (GRF 1-29) is the earliest GHRH analog, consisting of the first 29 amino acids of native GHRH without the DPP-IV-resistant substitutions. Its half-life of approximately 10-20 minutes requires twice-daily injection for meaningful GH elevation. CJC-1295's enhanced stability provides either sustained elevation (DAC version) or robust pulse amplification (Mod GRF 1-29) from the same or fewer injection frequency, making it pharmacokinetically superior for most research applications.

CJC-1295 vs. Tesamorelin: Tesamorelin is an FDA-approved GHRH analog used to reduce visceral adiposity in HIV-associated lipodystrophy. It has a half-life of approximately 26 minutes (shorter than Mod GRF 1-29) and requires daily injection. CJC-1295's longer half-life and the synergistic potential of combination protocols (particularly with ipamorelin) provide research advantages in terms of dosing flexibility and GH output magnitude.

CJC-1295 vs. MK-677 (Ibutamoren): MK-677 is an oral, non-peptide GH secretagogue that stimulates GH release through the ghrelin receptor. Its oral bioavailability is a significant convenience advantage, but it also stimulates appetite (a common ghrelin receptor effect), elevates cortisol and prolactin more than selective GHRP/GHRH combinations, and produces 24-hour continuous GH elevation that may increase insulin resistance. For researchers prioritizing GH selectivity and metabolic safety, CJC-1295 + ipamorelin offers a more targeted profile. Learn about peptide approaches to body composition in our weight loss peptides guide.

Maximizing the efficacy of CJC-1295 research protocols requires attention to several practical factors that influence GH release magnitude and downstream outcomes:

Fasting State: GH release in response to GHRH receptor stimulation is significantly attenuated by elevated blood glucose and insulin. Research protocols should ensure subjects are fasted for at least 2 hours before CJC-1295 administration. Post-injection, a 30-60 minute fasting window allows the GH pulse to peak before insulin-stimulating food intake. This timing consideration is less critical for the DAC version (which produces continuous rather than pulsatile elevation) but remains important for Mod GRF 1-29 protocols.

Body Composition Monitoring: Because CJC-1295's primary effects involve body composition changes that occur gradually over weeks, objective measurement methods are essential. DEXA scanning provides the most reliable assessment of lean mass and fat mass changes. Bioelectrical impedance analysis (BIA) is more accessible but less precise, particularly when GH-related water retention confounds fat-free mass measurements. Tracking waist circumference and skinfold measurements complements instrumental assessments.

Blood Work Protocol: Comprehensive blood work before, during (4-week intervals), and after CJC-1295 research protocols should include: IGF-1 (primary efficacy marker), fasting glucose and insulin (metabolic safety), HbA1c (for protocols exceeding 8 weeks), complete blood count, liver function panel, and lipid panel. Prolactin and cortisol levels are also worth monitoring, particularly when combining CJC-1295 with GHRPs other than ipamorelin.

Cycle Length and Rest Periods: Most research protocols run CJC-1295 for 8-16 weeks followed by a rest period of 4-8 weeks. The rationale for cycling includes preventing pituitary desensitization (downregulation of GHRH receptors from chronic stimulation), allowing insulin sensitivity to normalize, and enabling assessment of which effects are sustained after peptide discontinuation versus those that require ongoing administration. Some researchers maintain lower "maintenance" doses between intensive cycles to preserve partial benefits while allowing receptor sensitivity recovery.

The trajectory of CJC-1295 research points toward increasingly sophisticated protocols that optimize GH pulsatility, minimize metabolic side effects, and combine complementary peptides for synergistic outcomes. As the research peptide field matures, CJC-1295 remains one of the most well-characterized and widely studied GHRH analogs available. Browse quality-verified research peptides in our peptide catalog.